Featured Research

from universities, journals, and other organizations

Ashtray availability, signage may determine success of smoke-free legislation

Date:
September 4, 2013
Source:
Public Library of Science
Summary:
Signs banning smoking may not have as much of an impact on secondhand smoke concentrations as the presence of ashtrays or ashtray equivalents.

Signs banning smoking may not have as much of an impact on secondhand smoke concentrations as the presence of ashtrays or ashtray equivalents, according to research published September 4 in the open access journal PLOS ONE by Constantine Vardavas from the Harvard School of Public Health and colleagues from other institutions.

The authors measured the success of a non-enforced, nationwide smoke-free legislation in Greece by testing levels of secondhand smoke before the ban and for two years afterward. Following the 2010 legislation, secondhand smoke concentrations dropped immediately, but gradually increased again in subsequent measurements. However, all measurements after the ban remained significantly lower than levels of secondhand smoke measured before the legislation.

They found that outdoor or indoor signs that banned smoking did not correlate with levels of secondhand smoke in areas where signs were posted. However, the presence of ashtrays, or ashtray equivalents, such as candleholders, was strongly associated with a higher concentration of secondhand smoke. Based on their results, the authors conclude "While the public may be supportive of smoke-free legislation, adherence may decline rapidly if enforcement is limited or non-existent. Moreover, enforcement agencies should also focus on the comprehensive removal of ashtray equivalents that could act as a cue for smoking within a venue."


Story Source:

The above story is based on materials provided by Public Library of Science. Note: Materials may be edited for content and length.


Journal Reference:

  1. Constantine I. Vardavas, Israel Agaku, Evridiki Patelarou, Nektarios Anagnostopoulos, Chrysanthi Nakou, Vassiliki Dramba, Gianna Giourgouli, Paraskevi Argyropoulou, Antonis Antoniadis, Konstantinos Gourgoulianis, Despoina Ourda, Lambros Lazuras, Monique Bertic, Christos Lionis, Gregory Connolly, Panagiotis Behrakis. Ashtrays and Signage as Determinants of a Smoke-Free Legislation’s Success. PLoS ONE, 2013; 8 (9): e72945 DOI: 10.1371/journal.pone.0072945

Cite This Page:

Public Library of Science. "Ashtray availability, signage may determine success of smoke-free legislation." ScienceDaily. ScienceDaily, 4 September 2013. <www.sciencedaily.com/releases/2013/09/130904204127.htm>.
Public Library of Science. (2013, September 4). Ashtray availability, signage may determine success of smoke-free legislation. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2013/09/130904204127.htm
Public Library of Science. "Ashtray availability, signage may determine success of smoke-free legislation." ScienceDaily. www.sciencedaily.com/releases/2013/09/130904204127.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins